SCHEMBL208786

SCHEMBL208786

[CH2]CNC(=O)OC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.52
MEN1 O00255 1/20 0.48
GAA P10253 1/20 0.48
KMT2A Q03164 1/20 0.48
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
CA1 P00915 4/20 0.42
CA2 P00918 4/20 0.42
CA12 O43570 4/20 0.42
CA9 Q16790 2/20 0.42
EPHX1 P07099 1/20 0.42
CA7 P43166 2/20 0.41
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
CA14 Q9ULX7 2/20 0.39
APLNR P35414 1/20 0.39
CTSS P25774 2/20 0.39
CTSK P43235 2/20 0.39
HTT P42858 1/20 0.38
KDM4A O75164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28690736 0.85 TDP1 (0.47) TDP1MEN1GAAKMT2AMAOA
SCHEMBL27801417 0.82 TDP1 (0.50) TDP1MEN1GAAKMT2AMAOA
SCHEMBL166624 0.82 TDP1 (0.58) TDP1MEN1GAAKMT2AMAOA
SCHEMBL11989021 0.80 TDP1 (0.55) TDP1MEN1GAAKMT2AMAOA
SCHEMBL3341020 0.80 TDP1 (0.67) TDP1MEN1GAAKMT2AMAOA
SCHEMBL166207 0.79 TDP1 (0.65) TDP1MEN1GAAKMT2AMAOA
SCHEMBL7365542 0.79 TDP1 (0.34) TDP1MEN1GAAKMT2AMAOA
SCHEMBL605531 0.78 TDP1 (0.53) TDP1MEN1GAAKMT2AMAOA
SCHEMBL605532 0.78 TDP1 (0.59) TDP1MEN1GAAKMT2AMAOA
SCHEMBL12138378 0.78 TDP1 (0.53) TDP1MEN1GAAKMT2AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1476 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024131265-A1 COMPOUND FOR TREATING PI3Kγ-MEDIATED DISEASES AND USE THEREOF 中国科学院合肥物质科学研究院 2024-06-27 WO claimed
CN-118239953-A Compounds for the treatment of PI3K gamma mediated diseases and uses thereof 中国科学院合肥物质科学研究院 2024-06-25 CN claimed
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US claimed
CN-117298108-A Androgen receptor and glucocorticoid receptor dual-target inhibitor and application thereof 浙江师范大学 2023-12-29 CN claimed
US-20230126415-A1 OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF AKAGERA MEDICINES, INC. (US) 2023-04-27 US claimed
CN-114805367-B Triazole pyrimidine derivative and preparation method and application thereof 郑州大学 2023-04-07 CN claimed
CN-115803333-A Trinucleotide cap analogs, their preparation and use 生命技术公司 2023-03-14 CN claimed
CN-111527088-B Amino-methylpiperidine derivatives as kinase inhibitors 株式会社大熊制药 2022-12-30 CN claimed
CN-114805367-A Triazole pyrimidine derivative and preparation method and application thereof 郑州大学 2022-07-29 CN claimed
EP-3733674-B1 AMINO-METHYL PIPERIDINE DERIVATIVE AS KINASE INHIBITOR DAE WOONG PHARMA (KR) 2022-06-29 EP claimed
WO-1987003478-A2 MEDICAMENTS MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSC (DE) 1987-06-18 WO claimed
WO-1987003596-A2 NOVEL PHOSPHO-COMPOUNDS AND MEDICAMENTS CONTAINING THESE MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSC (DE) 1987-06-18 WO claimed
EP-0225608-A2 Medicine Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1987-06-16 EP claimed
EP-0224925-A2 Phosphorous compounds and medicines containing them Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1987-06-10 EP claimed
EP-0042154-B1 NEW CEPHEM COMPOUNDS AND PROCESSES FOR PREPARATION THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1987-04-15 EP claimed
US-4495182-A TREATMENT OF INFECTIOUS DISEASES;CEPHALOSPORINS AND DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1985-01-22 US claimed
EP-0007470-B1 CEPHEM COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-10-12 EP claimed
EP-0069872-A2 New cephem compounds and processes for preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-01-19 EP claimed
US-4268509-A BACTERICIDES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-05-19 US claimed
EP-0007470-A2 Cephem compounds, processes for their preparation and pharmaceutical compositions containing them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-02-06 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230126415-A1 OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF OXA1L, THPO, TBCD TDP1 3897/4885MEN1 1371/4885GAA 1148/4885
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 TDP1 1193/4885MEN1 2963/4885GAA 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.